CARLSBAD, Calif., March 2, 2007 (PRIME NEWSWIRE) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Financial Results and Highlights for 2006
When: Thursday, March 8, 2007, at 11:00 a.m. ET / 8:00 a.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our website listed
above.
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 15 drugs in development. Isis' drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis' partners are focused in disease areas such as ocular, viral and neurodegenerative diseases, and cancer. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.